How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Axon Therapies just landed $32mn and a new CEO—can an implant-free heart failure therapy really change the game? Find out how Axon Therapies’ $32M Series A and new CEO could speed implant-free heart failure trials and European expansion—see what it means for patients. bySoujanya RaviSeptember 25, 2025